KalVista Pharmaceuticals, Inc.
NASDAQ: KALV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Benjamin L. Palleiko
- Employees
- 275
- Headquarters
- Framingham, United States
- IPO year
- 2015
- Market cap
- $1.4B
- Website
- https://www.kalvista.com
Loading KALV…
Loading profile data…Frequently asked questions about KALV
What does KalVista Pharmaceuticals, Inc. (KALV) do?
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Fact...
Where does KALV trade?
KalVista Pharmaceuticals, Inc. (KALV) trades on the NASDAQ.
What sector is KALV in?
KalVista Pharmaceuticals, Inc. (KALV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of KalVista Pharmaceuticals, Inc.?
Benjamin L. Palleiko is the chief executive officer of KalVista Pharmaceuticals, Inc. (KALV).
Where is KalVista Pharmaceuticals, Inc. headquartered?
KalVista Pharmaceuticals, Inc. is headquartered in United States.
Does KALV pay a dividend?
KalVista Pharmaceuticals, Inc. (KALV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KALV go public?
KalVista Pharmaceuticals, Inc. (KALV) completed its initial public offering in 2015.